PHAXIAM Therapeutics (PHXM) Stock Price, News & Analysis

Company Overview

PHAXIAM Therapeutics (NASDAQ: PHXM) is a clinical-stage biopharmaceutical company dedicated to the development of messenger RNA (mRNA)–based therapies targeting rare genetic and metabolic disorders. Headquartered in Cambridge, Massachusetts, PHAXIAM leverages a proprietary lipid nanoparticle delivery platform designed to enhance tissue specificity and improve the stability of therapeutic mRNA sequences. The company’s core mission is to address unmet medical needs where traditional small-molecule and protein therapies have proven insufficient.

The PHAXIAM platform supports multiple therapeutic modalities, including protein replacement, gene editing via CRISPR components, and immunomodulatory applications. Its lead programs focus on rare liver diseases and inherited metabolic disorders, with preclinical data demonstrating robust target engagement and favorable safety profiles. Complementing these initiatives, the company is advancing additional pipeline candidates for central nervous system and oncology indications, positioning PHAXIAM as a versatile player in the mRNA innovation landscape.

Founded in 2018 by a team of molecular biologists and lipid nanotechnology experts from leading academic institutions, PHAXIAM has since established research and manufacturing collaborations across North America and Europe. The company completed a business combination with a special purpose acquisition company in 2023, transitioning to a publicly traded entity to accelerate its research, clinical development, and manufacturing scale-up activities.

PHAXIAM’s executive leadership is headed by Chief Executive Officer Dr. Michelle Chan, an industry veteran with over 20 years of experience in RNA therapeutics, and Chief Financial Officer John Martinez, who brings extensive expertise in biotech financing and operations. The company maintains research operations in Cambridge and a GMP manufacturing facility in Switzerland, fostering a global footprint to drive its mRNA therapeutic programs towards clinical milestones.

Key Stats

• Today's Range: $3.10 to $3.10
• 50-Day Range: $3.10 to $3.10
• 52-Week Range: $2.50 to $13.00
• Volume: N/A
• Average Volume: 2,472 shs
• Market Capitalization: $10.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PHXM Stock Analysis - Frequently Asked Questions

How have PHXM shares performed this year?

PHAXIAM Therapeutics' stock was trading at $3.10 on January 1st, 2025. Since then, PHXM stock has increased by 0.0% and is now trading at $3.10.

When did PHAXIAM Therapeutics' stock split?

PHAXIAM Therapeutics's stock reverse split on the morning of Wednesday, September 20th 2023.The 1-10 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of PHAXIAM Therapeutics?

Shares of PHXM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PHAXIAM Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PHAXIAM Therapeutics investors own include Salesforce (CRM), AbbVie (ABBV), Bank of America (BAC), Chevron (CVX), Merck & Co., Inc. (MRK), The PNC Financial Services Group (PNC) and AGCO (AGCO).

Company Calendar

• Today: 7/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PHXM
• CIK: 1624422
• Web: erytech.com
• Phone: 33478744438
• Fax: 33-4-78-75-56-29
• Employees: 49
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.23
• Current Ratio: 1.78
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.98 per share
• Price / Book: 0.39

Miscellaneous

• Outstanding Shares: 3,412,000
• Free Float: 3,346,000
• Market Cap: $10.58 million
• Optionable: No Data
• Beta: 2.35